Increased acute immune response during the meningo-encephalitic stage of Trypanosoma brucei rhodesiense sleeping sickness compared to Trypanosoma brucei gambiense

Translational Proteomics

Volumn 6, Issue , 2015, Pages 1-9

  Tiberti, Natalia ^a,j   Lejon, Veerle ^b   Mumba Ngoyi, Dieudonné ^c   Matovu, Enock ^d   Enyaru, John ^d   Walter, Nadia ^a   Fouda, Catherine ^a   Lutumba, Pascal ^e   Kristensson, Krister ^f   Bisser, Sylvie ^g   Mathu Ndung'u, Joseph ^h   Büscher, Philippe ⁱ   Sanchez, Jean Charles ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b Institut de recherche pour le développement   (France)

^c Institut National de Recherche Biomedicale   (Congo)

^d MAKERERE UNIVERSITY   (Uganda)

^e UNIVERSITY OF KINSHASA   (Congo)

^f KAROLINSKA INSTITUTE   (Sweden)

^g UNIVERSITÉ DE LIMOGES   (France)

^h FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

ⁱ INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^j UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

C reactive protein; Cerebrospinal fluid; Human African trypanosomiasis; Orosomucoid 1; Pathway analysis; T. b. gambiense; T. b. rhodesiense

Indexed keywords

C REACTIVE PROTEIN; COMPLEMENT COMPONENT C9; LIVER X RECEPTOR; OROSOMUCOID; OROSOMUCOID 1; RETINOID X RECEPTOR; UNCLASSIFIED DRUG;

ACUTE DISEASE; ADULT; AFRICAN TRYPANOSOMIASIS; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MALE; MENINGOENCEPHALITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION; SPECIES COMPARISON; TRYPANOSOMA; TRYPANOSOMA RHODESIENSE;

TRYPANOSOMA BRUCEI; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMA BRUCEI RHODESIENSE;

EID: 84994464101     PISSN: 22129626     EISSN: 22129634     Source Type: Journal    
DOI: 10.1016/j.trprot.2014.11.001     Document Type: Article

References (53)

1. Brun R., Blum J., Chappuis F., Burri C. Human African trypanosomiasis. Lancet 2010, 375(9709):148-159. arxiv:/19833383, 10.1016/S0140-6736(09)60829-1.
2. Simarro P.P., Cecchi G., Paone M., Franco J.R., Diarra A., Ruiz J.A., et al. The atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Int J Health Geogr 2010, 9:57. arxiv:/21040555, 10.1186/1476-072X-9-57.
3. Simarro P.P., Jannin J., Cattand P. Eliminating human African trypanosomiasis: where do we stand and what comes next?. PLoS Med 2008, 5(2):e55. arxiv:/18303943, 10.1371/journal.pmed.0050055.
4. Simarro P.P., Diarra A., Ruiz Postigo J.A., Franco J.R., Jannin J.G. The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000-2009: the way forward. PLoS Negl Trop Dis 2011, 5(2):e1007. arxiv:/21364972, 10.1371/journal.pntd.0001007.
5. Sternberg J.M. Human African trypanosomiasis: clinical presentation and immune response. Parasite Immunol 2004, 26(11-12):469-476. arxiv:/15771682, 10.1111/j.0141-9838.2004.00731.x.
6. Kennedy P.G. Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest 2004, 113(4):496-504. arxiv:/14966556, 10.1172/JCI21052.
7. Blum J., Schmid C., Burri C. Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop 2006, 97(1):55-64. arxiv:/16157286, 10.1016/j.actatropica.2005.08.001.
8. Lejon V., Büscher P. Review article: cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post-treatment follow-up. Trop Med Int Health 2005, 10(5):395-403. arxiv:/15860085, 10.1111/j.1365-3156.2005.01403.x.
9. Kuepfer I., Hhary E.P., Allan M., Edielu A., Burri C., Blum J.A. Clinical presentation of T. b. rhodesiense sleeping sickness in second stage patients from Tanzania and Uganda. PLoS Neglect Trop Dis 2011, 5(3):e968. arxiv:/21407802, 10.1371/journal.pntd.0000968.
10. Maudlin I. African trypanosomiasis. Ann Trop Med Parasitol 2006, 100(8):679-701. arxiv:/17227648, 10.1179/136485906X112211.
11. Chappuis F., Loutan L., Simarro P., Lejon V., Büscher P. Options for field diagnosis of human African trypanosomiasis. Clin Microbiol Rev 2005, 18(1):133-146. arxiv:/15653823, 10.1128/CMR.18.1.133-146.2005.
12. Burri C. Chemotherapy against human African trypanosomiasis: is there a road to success?. Parasitology 2010, 137(14):1987-1994. arxiv:/20961469, 10.1017/S0031182010001137.
13. Chappuis F., Udayraj N., Stietenroth K., Meussen A., Bovier P.A. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Clin Infect Dis 2005, 41(5):748-751. arxiv:/16080099, 10.1086/432576.
14. Priotto G., Kasparian S., Mutombo W., Ngouama D., Ghorashian S., Arnold U., et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 2009, 374(9683):56-64. arxiv:/19559476, 10.1016/S0140-6736(09)61117-X.
15. Control and surveillance of human African trypanosomiasis. Report of a WHO Expert Committee. WHO Tech Rep S 2013, 984. WHO.
16. Tiberti N., Hainard A., Lejon V., Courtioux B., Matovu E., Enyaru J.C., et al. Cerebrospinal fluid neopterin as marker of the meningo-encephalitic stage of Trypanosoma brucei gambiense sleeping sickness. PLoS One 2012, 7(7):e40909. arxiv:/22815865, 10.1371/journal.pone.0040909.
17. Tiberti N., Matovu E., Hainard A., Enyaru J.C., Lejon V., Robin X., et al. New biomarkers for stage determination in Trypanosoma brucei rhodesiense sleeping sickness patients. Clin Transl Med 2013, 2(1):1. arxiv:/23369533, 10.1186/2001-1326-2-1.
18. MacLean L., Odiit M., Sternberg J.M. Nitric oxide and cytokine synthesis in human African trypanosomiasis. J Infect Dis 2001, 184(8):1086-1090. arxiv:/11574928, 10.1086/323479.
19. Maclean L., Odiit M., Sternberg J.M. Intrathecal cytokine responses in Trypanosoma brucei rhodesiense sleeping sickness patients. Trans R Soc Trop Med Hyg 2006, 100(3):270-275. arxiv:/16343570, 10.1016/j.trstmh.2005.03.013.
20. Lejon V., Lardon J., Kenis G., Pinoges L., Legros D., Bisser S., et al. Interleukin (IL)-6, IL-8 and IL-10 in serum and CSF of Trypanosoma brucei gambiense sleeping sickness patients before and after treatment. Trans R Soc Trop Med Hyg 2002, 96(3):329-333. arxiv:/12174791, 10.1016/S0035-9203(02)90115-X.
21. Amin D.N., Ngoyi D.M., Nhkwachi G.M., Palomba M., Rottenberg M., Büscher P., et al. Identification of stage biomarkers for human African trypanosomiasis. Am J Trop Med Hyg 2010, 82(6):983-990. arxiv:/20519589, 10.4269/ajtmh.2010.09-0770.
22. Lejon V., Reiber H., Legros D., Djé N., Magnus E., Wouters I., et al. Intrathecal immune response pattern for improved diagnosis of central nervous system involvement in trypanosomiasis. J Infect Dis 2003, 187(9):1475-1483. arxiv:/12717630, 10.1086/374645.
23. MacLean L., Reiber H., Kennedy P.G., Sternberg J.M. Stage progression and neurological symptoms in Trypanosoma brucei rhodesiense sleeping sickness: role of the CNS inflammatory response. PLoS Negl Trop Dis 2012, 6(10):e1857. arxiv:/23145191, 10.1371/journal.pntd.0001857.
24. Mumba Ngoyi D., Lejon V., Pyana P., Boelaert M., Ilunga M., Menten J., et al. How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness. J Infect Dis 2010, 201(3):453-463. arxiv:/20047500, 10.1086/649917.
25. Dayon L., Hainard A., Licker V., Turck N., Kuhn K., Hochstrasser D.F., et al. Relative quantification of proteins in human cerebrospinal fluids by MS/MS using 6-plex isobaric tags. Anal Chem 2008, 80(8):2921-2931. arxiv:/18312001, 10.1021/ac702422x.
26. Dayon L., Pasquarello C., Hoogland C., Sanchez J.C., Scherl A. Combining low- and high-energy tandem mass spectra for optimized peptide quantification with isobaric tags. J Proteomics 2010, 73(4):769-777. arxiv:/19903544, 10.1016/j.jprot.2009.10.015.
27. Gluck F., Hoogland C., Antinori P., Robin X., Nikitin F., Zufferey A., et al. EasyProt - an easy-to-use graphical platform for proteomics data analysis. J Proteomics 2013, 79:146-160. arxiv:/23277275, 10.1016/j.jprot.2012.12.012.
28. Breitwieser F.P., Müller A., Dayon L., Köcher T., Hainard A., Pichler P., et al. General statistical modeling of data from protein relative expression isobaric tags. J Proteome Res 2011, 10(6):2758-2766. arxiv:/21526793, 10.1021/pr1012784.
29. Vizcaíno J.A., Deutsch E.W., Wang R., Csordas A., Reisinger F., Ríos D., et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat Biotechnol 2014, 32(3):223-226. arxiv:/24727771, 10.1038/nbt.2839.
30. Vizcaíno J.A., CÔté R.G., Csordas A., Dianes J.A., Fabregat A., Foster J.M., et al. The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res 2013, 41:D1063-D1069. arxiv:/23203882, 10.1093/nar/gks1262.
31. Overgaard A.J., Thingholm T.E., Larsen M.R., Tarnow L., Rossing P., McGuire J.N., et al. Quantitative iTRAQ-based proteomic identification of candidate biomarkers for diabetic nephropathy in plasma of Type 1 diabetic patients. Clin Proteomics 2010, 6(4):105-114. arxiv:/21124997, 10.1007/s12014-010-9053-0.
32. Munday D.C., Hiscox J.A., Barr J.N. Quantitative proteomic analysis of A549 cells infected with human respiratory syncytial virus subgroup B using SILAC coupled to LC-MS/MS. Proteomics 2010, 10(23):4320-4334. arxiv:/21110324, 10.1002/pmic.201000228.
33. Müller T., Schrötter A., Loosse C., Helling S., Stephan C., Ahrens M., et al. Sense and nonsense of pathway analysis software in proteomics. J Proteome Res 2011, 10(12):5398-5408. arxiv:/21978018, 10.1021/pr200654k.
34. Kennedy P.G. Diagnostic and neuropathogenesis issues in human African trypanosomiasis. Int J Parasitol 2006, 36(5):505-512. arxiv:/16546191, 10.1016/j.ijpara.2006.01.012.
35. Kennedy P.G. Human African trypanosomiasis-neurological aspects. J Neurol 2006, 253(4):411-416. arxiv:/16541214, 10.1007/s00415-006-0093-3.
36. Rodgers J. Trypanosomiasis and the brain. Parasitology 2010, 137(14):1995-2006. arxiv:/20028610, 10.1017/S0031182009991806.
37. Kristensson K., Nygård M., Bertini G., Bentivoglio M. African trypanosome infections of the nervous system: parasite entry and effects on sleep and synaptic functions. Prog Neurobiol 2010, 91(2):152-171. arxiv:/19995590, 10.1016/j.pneurobio.2009.12.001.
38. Sternberg J.M., Rodgers J., Bradley B., Maclean L., Murray M., Kennedy P.G. Meningoencephalitic African trypanosomiasis: brain IL-10 and IL-6 are associated with protection from neuro-inflammatory pathology. J Neuroimmunol 2005, 167(1-2):81-89. arxiv:/16054238, 10.1016/j.jneuroim.2005.06.017.
39. Masocha W., Robertson B., Rottenberg M.E., Mhlanga J., Sorokin L., Kristensson K. Cerebral vessel laminins and IFN-gamma define Trypanosoma brucei brucei penetration of the blood-brain barrier. J Clin Invest 2004, 114(5):689-694. arxiv:/15343387, 10.1172/JCI22104.
40. Tosi M.F. Innate immune responses to infection. J Allergy Clin Immunol 2005, 116(2):241-249. quiz 50. arxiv:/16083775.
41. Ansar W., Ghosh S. C-reactive protein and the biology of disease. Immunol Res 2013, 56(1):131-142. arxiv:/23371836, 10.1007/s12026-013-8384-0.
42. Volanakis J.E. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001, 38(2-3):189-197. arxiv:/11532280, 10.1016/S0161-5890(01)00042-6.
43. Rajs G., Finzi-Yeheskel Z., Rajs A., Mayer M. C-reactive protein concentrations in cerebral spinal fluid in gram-positive and gram-negative bacterial meningitis. Clin Chem 2002, 48(3):591-592. arxiv:/11861461.
44. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res 2000, 887(1):80-89. arxiv:/11134592, 10.1016/S0006-8993(00)02970-X.
45. Hsuchou H., Kastin A.J., Mishra P.K., Pan W. C-reactive protein increases BBB permeability: implications for obesity and neuroinflammation. Cell Physiol Biochem 2012, 30(5):1109-1119. arxiv:/23018453, 10.1159/000343302.
46. Ceciliani F., Pocacqua V. The acute phase protein alpha1-acid glycoprotein: a model for altered glycosylation during diseases. Curr Protein Pept Sci 2007, 8(1):91-108. arxiv:/17305563, 10.2174/138920307779941497.
47. Fournier T., Medjoubi-N N., Porquet D. Alpha-1-acid glycoprotein. Biochim Biophys Acta 2000, 1482(1-2):157-171. arxiv:/11058758, 10.1016/S0167-4838(00)00153-9.
48. Feelders R.A., Vreugdenhil G., Eggermont A.M., Kuiper-Kramer P.A., van Eijk H.G., Swaak A.J. Regulation of iron metabolism in the acute-phase response: interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients. Eur J Clin Invest 1998, 28(7):520-527. arxiv:/9726030, 10.1046/j.1365-2362.1998.00323.x.
49. Saint-Pol J., Candela P., Fenart L., Gosselet F. The LXR/RXR approaches in Alzheimer's disease: is the blood-brain barrier the forgotten partner?. J Alzheimers Dis Parkinsonism 2013, 3:1000e131.
50. Panzenboeck U., Kratzer I., Sovic A., Wintersperger A., Bernhart E., Hammer A., et al. Regulatory effects of synthetic liver X receptor- and peroxisome-proliferator activated receptor agonists on sterol transport pathways in polarized cerebrovascular endothelial cells. Int J Biochem Cell Biol 2006, 38(8):1314-1329. arxiv:/16530456, 10.1016/j.biocel.2006.01.013.
51. Morrison L.J., McLellan S., Sweeney L., Chan C.N., MacLeod A., Tait A., et al. Role for parasite genetic diversity in differential host responses to Trypanosoma brucei infection. Infect Immun 2010, 78(3):1096-1108. arxiv:/20086091, 10.1128/IAI.00943-09.
52. Maclean L., Odiit M., Macleod A., Morrison L., Sweeney L., Cooper A., et al. Spatially and genetically distinct African trypanosome virulence variants defined by host interferon-gamma response. J Infect Dis 2007, 196(11):1620-1628. arxiv:/18008245, 10.1086/522011.
53. Picozzi K., Fèvre E.M., Odiit M., Carrington M., Eisler M.C., Maudlin I., et al. Sleeping sickness in Uganda: a thin line between two fatal diseases. BMJ 2005, 331(7527):1238-1241. arxiv:/16308383, 10.1136/bmj.331.7527.1238.